Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial

Phase III noninferiority trial examining efficacy and safety of converting stable renal transplant recipients from twice-daily tacrolimus to a novel extended-release once-daily tacrolimus formulation (LCPT) with a controlled agglomeration technology. Controls maintained tacrolimus twice daily. The p...

Full description

Bibliographic Details
Main Authors: Bunnapradist, S, Ciechanowski, K, West-Thielke, P, Mulgaonkar, S, Rostaing, L, Vasudev, B, Budde, K
Format: Online
Language:English
Published: Blackwell Publishing Ltd 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613750/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613750/

Similar Items